As a result, HDIs may exert their anti-cancer action, at least in part, by decreasing tumour cell responsiveness to TNF-mediated activation of the NF-κB pathway, as TNF-receptor-1 expression and TNF-mediated NF-κB nuclear translocation were all reduced in HDI-treated NSCLC cells [57]. The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.